Contents
Can We Prevent Progression in Chronic Myeloid Leukemia?
Published: Jul 09, 2024
Preventing the progression of Chronic Myeloid Leukemia (CML) is pivotal in managing the disease effectively. This article delves into methods that can help control CML and prevent it from advancing to more severe stages.
Understanding CML Progression
CML begins in the chronic phase, which is generally manageable, but it can progress to more severe phases if not effectively controlled. The goal is to keep the disease from advancing to the accelerated or blast phases, where treatment becomes more challenging. Recognizing and addressing factors that contribute to progression is key to successful management.
Role of TKIs in Prevention
Tyrosine kinase inhibitors (TKIs) are crucial in preventing CML progression. By targeting the BCR::ABL1 protein, TKIs help maintain the disease in its chronic phase, reducing the risk of progression. Consistent and correct use of TKIs, along with regular monitoring, is essential to prevent the disease from advancing.
Monitoring for Success
Regular monitoring through blood tests and molecular analysis is vital in detecting early signs of progression. Timely intervention based on monitoring results can help prevent the disease from advancing to more aggressive phases, thereby improving patient outcomes.
Frequently Asked Questions
TKIs target the BCR::ABL1 protein, keeping CML in the chronic phase.
Regular monitoring helps detect early signs of progression for timely intervention.
The goal is to maintain CML in the chronic phase and prevent progression.
Stay Ahead
Preventing CML progression is crucial for effective disease management and better patient outcomes.
References
- Marin D, Khorashad JS, Foroni L, et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol 2009; 145:373.
- Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia. Blood 2010; 116:3758.
This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic. Always discuss health information with your healthcare provider.
AI Doctor Visit Required
Appointments available 24/7
Top licensed doctors
Available in all 50 states
Full service care
Prescriptions, referrals & treatment
No insurance needed
All notes available in Doctronic
15-min consultation. No hidden costs.
AI Doctor Visit Required
Please Chat With Our AI Doctor First
Our AI doctor assessment helps our human doctors prepare for your video visit and provide better care
For safety reasons we have been forced to end this consultation.
If you believe this is a medical emergency please call 911 or your local emergency services immediately.
If you are experiencing emotional distress, please call the the Suicide & Crisis Lifeline at 988 or your local crisis services immediately.
Contact us
You can also email us at help@doctronic.ai
We aim to reply within 5-7 days
How likely are you to recommend Doctronic to friends or family?